-James A Roth Researcher Activity Profile

Research Author Detailed Information 

James A Roth Publication Rate By Year

James A Roth has published 1 paper(s) in 1949, 2 paper(s) in 2003, 6 paper(s) in 2006, 22 paper(s) in 2007, 5 paper(s) in 2008, for a total of 36 research publications in total.

James A Ja Roth Author Information

LAST NAME: roth

FIRST NAME: James A

INITIALS: ja

AFFILIATION:

Papers

James A Roth's Publication Record

1. Exotic and emerging diseases of animals: an internet course for veterinary students. Year Published: 2003
College of Veterinary Medicine, Iowa State University, Ames, Iowa 50011, USA.
2. Homeostatic and toxic mechanisms regulating manganese uptake, retention, and elimination. Year Published: 2006
Department of Pharmacology and Toxicology, University at Buffalo. Buffalo, New York 14214, USA. jaroth@buffalo.edu
3. DMT1: which metals does it transport? Year Published: 2006
Department of Biochemistry, SUNY at Buffalo, Buffalo, NY 14214, USA. mgarrick@buffalo.edu
4. The 3p21.3 tumor suppressor NPRL2 plays an important role in cisplatin-induced resistance in human non-small-cell lung cancer cells. Year Published: 2006
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M.D. Anderson Cancer Center, Houston, TX 77030, USA.
5. Monitoring responses by use of five-color flow cytometry in subsets of peripheral T cells obtained from cattle inoculated with a killed Mycobacterium avium subsp paratuberculosis vaccine. Year Published: 2006
Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.
6. Enhancement of adenoviral MDA-7-mediated cell killing in human lung cancer cells by geldanamycin and its 17-allyl- amino-17-demethoxy analogue. Year Published: 2006
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd., Box 445, Houston, TX 77030, USA. apataer@mdanderson.org
7. Aberrant promoter methylation profile and association with survival in patients with non-small cell lung cancer. Year Published: 2006
Department of Epidemiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
8. Expression of the 1B isoforms of divalent metal transporter (DMT1) is regulated by interaction of NF-Y with a CCAAT-box element near the transcription start site. Year Published: 2007
Department of Pharmacology and Toxicology, School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York 14214, USA.
9. Pandemic influenza planning: shouldn't swine and poultry workers be included? Year Published: 2007
Center for Emerging Infectious Diseases, College of Public Health University of Iowa, 200 Hawkins Drive, Iowa City, IA 52242, USA. gregory-gray@uiowa.edu
10. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Year Published: 2007
Division of Translational Research, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas, USA.
11. Tumor suppressor 101F6 and ascorbate synergistically and selectively inhibit non-small cell lung cancer growth by caspase-independent apoptosis and autophagy. Year Published: 2007
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
12. Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. Year Published: 2007
Gastrointestinal Oncology Service, Memorial Sloan-Kettering Cancer Center, New York, NY 10021, USA. kelsend@mskcc.org
13. Tumor-specific activation of human telomerase reverses transcriptase promoter activity by activating enhancer-binding protein-2beta in human lung cancer cells. Year Published: 2007
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
14. Advances in immunology and vaccine discovery report of the United States-European Commission workshop. Year Published: 2007
Animal Production and Protection, Agriculture Research Service, United States Department of Agriculture, 5601 Sunnyside Avenue, Beltsville, MD 20705, United States.
15. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Year Published: 2007
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
16. Fragile histidine triad-mediated tumor suppression of lung cancer by targeting multiple components of the Ras/Rho GTPase molecular switch. Year Published: 2007
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX 77030, USA.
17. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. Year Published: 2007
Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
18. Cancer targeting using tumor suppressor genes. Year Published: 2007
Department of Clinical Research and Development, Introgen Research Institute, Introgen Therapeutics Inc., Houston, Texas 77030, USA. s.chada@introgen.com
19. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. Year Published: 2007
Department of Experimental Therapeutics, The University of Texas M. D. Anderson Cancer Center, Box 19, 1515 Holcombe Blvd, Houston, TX 77030, USA. whittelm@mdanderson.org
20. Advances in immunology and vaccine discovery report of the United States-European Commission workshop. Year Published: 2007
Animal Production and Protection, Agriculture Research Service, United States Department of Agriculture, 5601 Sunnyside Avenue, Beltsville, MD 20705, United States.
21. Cancer targeting using tumor suppressor genes. Year Published: 2007
Department of Clinical Research and Development, Introgen Research Institute, Introgen Therapeutics Inc., Houston, Texas 77030, USA. s.chada@introgen.com
22. Characterizing the cancer genome in lung adenocarcinoma. Year Published: 2007
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
23. Characterizing the cancer genome in lung adenocarcinoma. Year Published: 2007
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
24. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Year Published: 2007
1Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
25. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Year Published: 2007
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
26. The double-stranded RNA-activated protein kinase mediates radiation resistance in mouse embryo fibroblasts through nuclear factor kappaB and Akt activation. Year Published: 2007
Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA.
27. A comparison of rural and urban birth sex ratios for the total, the white and the colored U.S. population. Year Published: 1949
28. Comparison of limited surgery and three-dimensional conformal radiation in high-risk patients with stage I non-small cell lung cancer. Year Published: 2007
Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
29. Characterizing the cancer genome in lung adenocarcinoma. Year Published: 2007
Department of Medical Oncology and Center for Cancer Genome Discovery, Dana-Farber Cancer Institute, Boston, Massachusetts 02115, USA.
30. Enhancement of antitumor activity of cisplatin in human lung cancer cells by tumor suppressor FUS1. Year Published: 2007
Department of Thoracic and Cardiovascular Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
31. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Year Published: 2008
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
32. [2-methoxyestradiol induces p53 independent apoptosis in pancratic carcinoma and inhibits growth of lung metastasis] Year Published: 2003
University of Texas, M.D. Anderson Cancer Center, Houston, Texas, USA.
33. Loss and reduction of FUS1 protein expression is a frequent phenomenon in the pathogenesis of lung cancer. Year Published: 2008
Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030-4009, USA.
34. Tumor Suppressor FUS1 Signaling Pathway. Year Published: 2008
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas.
35. Tumor suppressor FUS1 signaling pathway. Year Published: 2008
Section of Thoracic Molecular Oncology, Department of Thoracic and Cardiovascular Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77230-1402, USA. lji@mdanderson.org
36. Humoral and T cell-mediated immune responses to bivalent killed bovine viral diarrhea virus vaccine in beef cattle. Year Published: 2008
Department of Veterinary Microbiology and Preventive Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA 50011, USA.